The Nodify XL2 test is a blood-based lung nodule test that integrates five clinical risk factors with the measurement of two circulating proteins in patients with low to moderate risk lung nodules.
Using a systems biology approach, hundreds of proteins implicated in lung cancer tissues studies were assessed. The ratio of two proteins, LG3BP to C163A, was ultimately selected because of its performance in classifying benign nodules.
When the test is used in clinical practice, 80% of patients receive a Likely Benign or Reduced Risk test result and have a lower risk of malignancy than indicated by traditional risk factors alone.
Test reports are personalized by calculating a post-Nodify XL2 risk of malignancy based on the test result and the pre-test risk according to the Solitary Pulmonary Nodule Calculator. These test results support clinical decision-making by helping physicians identify patients who may benefit from CT surveillance.
The Nodify XL2 test was clinically validated in the PANOPTIC trial. The high sensitivity and negative predictive value of the test help instill confidence that a patient can be safely monitored with follow-up CT scans.
The Nodify XL2 test is also covered by Medicare, making it more accessible to covered beneficiaries with just a standard blood draw. With most test results indicating a lower risk of malignancy, the Nodify XL2 test helps physicians identify patients with likely benign nodules and reduce unnecessary invasive procedures.
- What does the Nodify XL2 test measure ( Download)
- What does the Nodify CDT test measure ( Download)
- How does Nodify Lung™ testing work ( Download)
- Enhanced Performance of the Nodify XL2 Blood-Based Lung Nodule Test ( Download)
- Case studies using Nodify Lung™ testing ( Download)
- Reclassifying malignancy risk in indeterminate pulmonary nodules using Nodify Lung™ testing strategy ( Download)
- The Importance of Nodify ( Download)
- Using a Blood-Based Biomarker in Patients with Pulmonary Nodules in a Real-World Observational Study ( Download)
- Using Biomarker-Based Risk Assessments to Inform Lung Nodule Referral Decisions ( Download)
- Nodify Lung Collection Video – 2021 ( Download)
- Optimizing Diagnosis of Malignant Lung Nodules with the Use of Biomarker Testing and Robotic Bronch ( Download)
- WEBINAR REPLAY: Evolution of Clinical Evidence of the Blood-based Nodify Lung Nodule Risk Assessment ( Download)
- The Use of Blood-Based Biomarkers in the Evaluation and Management of Pulmonary Nodules ( Download)
- Evaluating lung nodules during the COVID-19 pandemic using blood-based biomarkers ( Download)
- Patients and Coverage ( Download)
